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Abstract 
Nicotinic ligands can be potentially useful as drugs for the management of several important 
pathologies as well as pharmacological tools to characterize nicotinic receptor subtypes. The 
design of new nicotinic ligands has been carried out by applying the 3D database search method; 
thus, the Cambridge Structural Database has been scanned with a query consisting in a 
pharmacophore substructure with 3D constraints. The nicotinic pharmacophoric features have 
been obtained from the structure of pyrido[3,4-b]homotropane (PHT), which represents a rigid 
template. The results of the query suggested the aminoalkylquinoline moiety as simple scaffold, 
and it was further refined using molecular modeling. Some of the synthesized compounds were 
found to interact with the central nicotinic receptor on rat cerebral cortex, showing affinity in the 
nanomolar range and displaying analgesic properties. The possible binding mode of these 
substances with a homology-built model of the nicotinic receptor has been analyzed by means of 
induced fit studies. 
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Introduction 
 
Neurodegenerative disorders are characterized by a progressive and irreversible loss of neurons 
in the CNS. Their aetiology is unknown, but genetic alterations, oxidative stress, environmental 
factors, excitotoxicity and age are thought to be important risk factors. Degeneration is localized 
in specific areas of the CNS and it is characterized by particular histopathological changes, some 
of which are due to the formation of amorphous protein deposits known as amyloid. These 
“misfolded” proteins adopt β-sheet structures and aggregate spontaneously into similar extended 
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fibrils despite their widely divergent primary sequences. Many of these peptides can form ion-
permeable channels in vitro and possibly in vivo, and this may be relevant for their toxicity.1
Probably the best studied amyloid deposit is that found in Alzheimer's disease (AD). The 
pathological changes described in the post mortem brains of Alzheimer disease patients include 
senile plaques, which are formed by 40- or 42-amino-acid peptides called amyloid-β, whose 
level in the brain correlates with the onset and severity of memory impairments. This peptide, 
particularly the 42-amino-acid form, is highly hydrophobic and accumulates both extracellularly 
in plaques and intracellularly. Soluble extracellular amyloid-β may initiate memory impairments 
before the accumulation of plaques. 
AD is a form of dementia characterized by a deficit in the central cholinergic transmission, 
caused by degeneration of the basal forebrain cholinergic neurons innervating cortex and 
hippocampus, which produces difficulties in attention and cognitive impairment. 
Pharmacological treatment based on the "cholinergic hypothesis" has led to the development of 
acetylcholinesterase inhibitors: tacrine, donepezil, galanthamine and rivastigmine are the only 
drugs approved for AD together with memantine,2,3 which is classified as an antagonist of the 
glutamatergic NMDA receptor, although  it has been recently reported that it blocks the α7 
receptor in hippocampal neurons more potently than NMDA receptors.4,5
A significant loss of nicotinic cholinergic receptors (nAChR) has been found in post mortem 
brains of AD patients, and a deficit of nAChRs is observed also in vivo by means of positron 
emission tomography (PET) studies; a significant correlation has been found between nicotinic 
deficit and cognitive impairment.6 Moreover, epidemiological studies have suggested that 
smokers exhibit a lower incidence of AD and Parkinson's Disease (PD), and there are several 
studies reporting the neuroprotective effect of  nicotine under several kinds of neurotoxic 
conditions.7
Nicotine is the prototype of agonists for the nicotinic receptors, which are the best studied 
members of the family of Ligand Gated Ion Channels (LGIC). They are composed of five 
subunits assembled to form a cation permeable pore. To date, 17 nAChR subunits have been 
cloned, and among them five are muscle-type and the others are found in neurons and sensory 
epithelia. While the five muscle-type nAChR subunits have been found to assemble into only 
two possible combinations (α2βγδ or α2βεδ), the 12 neuronal nAChR subunits can form a large 
number of nAChR subtypes, differing in terms of ligand pharmacology, cation permeability, 
activation and desensitization kinetics. Studies using cloned receptors have shown that the α(2-6) 
and β(2-4) subunits are involved in the formation of heteropentameric nAChR complexes, while 
the α7, α8, and α9 subunits form homopentameric receptor complexes, and the α10 nAChR 
subunit cannot form a functional nAChR alone, but it does together with α9. As far as native 
neuronal receptors are concerned, the predominant nAChR subunits in the CNS are α4, β2, and 
α7, whereas α3 and β4 are the prevalent subunits in the periphery. The majority of nAChRs in 
the CNS (about 90%) are α4β2* receptors, and α7* nAChR is the other major CNS subtype. The 
distribution of the other nAChR subunits in the CNS is much more limited. 8
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The agonist binding sites are located at the interface between α and non-α subunits, and are 
formed by a principal component (loops A-C on the α subunit) and the complementary 
component (loops D-E on the non-α subunit). The number of possible binding sites depends on 
the number (and type) of α subunits in the stoichiometry of the receptor: therefore, in the muscle-
type there are two non-equivalent binding sites at the α-γ and α-δ interfaces, while in the 
neuronal-type the binding sites are two (α-β interface) in the heteromeric receptor and five in the 
homomeric receptor. 
nAChRs are located both pre- and post synaptically; presynaptic nAChRs modulate the 
release of ACh, glutamate and other neurotransmitters throughout the CNS.9 Regarding the 
function of nicotinic receptors, a lot of work has been performed using knock-out mice, showing 
that deletion of α4 and β2 subunits affects locomotion, reinforcement and memory and 
learning,10 which explains the pharmacological effects of nicotine. 
Several nicotinic agonists from different chemical classes have been studied in cognition 
models, and some of them have also entered clinical trials for AD: both α4β2 and α7 selective 
agonists show cognition-enhancing properties, being able to induce long-term potentiation 
(LTP), through an increase in glutamatergic transmission obtained by activating an α4β2 
presynaptic receptor on cholinergic neurons, or an α7 receptor on glutamatergic neurons.11 
Moreover, as far as AD is concerned, there is evidence that the nicotinic receptor may be the 
target of the toxic effect of Aβ1-42.12 In fact, it has been reported that Aβ1-42 binds with high 
affinity to nicotinic receptors, causing activation at picomolar doses and inhibition at higher 
doses, the non-α7 being more sensitive than the α7.13-16 The action of Aβ1-42 through the α7 
nicotinic receptor has, as a consequence, a reduction of glutamatergic transmission and an 
inhibition of synaptic plasticity.17
 
 
 
Chart 1 
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It is worth highlighting that the importance of the nicotinic receptor is due not only to its 
involvement in AD and PD, but also into a variety of psychiatric disorders or pathological 
conditions. Involvement of nicotinic receptor in schizophrenia and depression was first suggested 
by the high percentage of smokers among schizophrenics;18 there is evidence that the α7 
nicotinic receptor expression and function is reduced in such patients, which suggests to consider 
α7 selective full or partial agonists as possible therapeutic interventions.19 A relationships has 
also been found between smoke and depression,20 and both agonists (such as nicotine) and 
antagonists are effective in animal models of depression.21,22 Several nicotinic agonists are under 
development as analgesics, 23 and ABT-089, a compound in phase II for AD, is also under 
evaluation for Attention-Deficit Hyperactivity Disorder (ADHD) in adults.24 Varenicline, an 
orally active α4β2 nicotinic partial agonist, is now in clinical trials for smoking cessation.25 
Finally, nicotinic antagonists may be useful in autism and in some forms of genetic epilepsy.26,27
It is obviously important to determine which subtype of nicotinic receptor is involved in each 
of these disorders, in order to design specific modulators, but this is made difficult by the high 
number of subunits that can co-assemble in many different ways, by the low abundance of some 
of them in the brain, and by the lack of selective ligands to study the role of nAChR under 
physiological or pathological conditions. So the search for new and selective nicotinic ligands is 
still very important. 
 
 
Results and Discussion 
 
The design of new nicotinic ligands has been performed in different ways. Historically, the most 
popular approach starts from natural products such as nicotine, cytisine or epibatidine as lead 
compounds;28 the design and synthesis of varenicline is a recent example of drug design starting 
from the cytisus alkaloid cytisine (Chart 1).29 Rapid progress in the techniques developed for 
structural biology studies is expected to make the structure-based drug design approach possible; 
at present, the homology models based on the X-ray structures of Acetylcholine Binding Protein 
(AChBP),30-33 representing only the extracellular part of the receptor which contains the ligand 
binding domain, have been used mainly to rationalize existing data.34-37 Recently, models of the 
whole muscle-type38 or α739 receptors, based on the cryo-electron microscopy data of the 
membrane domain collected on Torpedo Marmorata nAChRs,40 have been developed, and 
hopefully they will overcome the limitations inherent to the previous models.41
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Chart 2 
 
To look for new ideas for the discovery of novel nicotinic ligands, we thought it interesting 
to apply the 3D database searching approach,42 a method which was used, although with some 
differences, almost 20 years ago by Sheridan and Venkataraghavan.43 Therefore,44 the 
Cambridge Structural Database was scanned with a suitable query, searching for compounds 
showing the pharmacophoric features typical for the interaction with the nicotinic receptor: an H-
bond acceptor group and a potentially-cationic nitrogen at a certain distance and with a precise 
spatial orientation. The query was built up starting from the structures of pyrido[3,4-
b]homotropane (PHT):45,46 this is a fully rigid high affinity ligand, showing  the two 
pharmacophoric points at a distance of 4.75 Å. The proposed values for this pharmacophoric 
feature range from 4.5 to 6.1 Å.47-49
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Table 1. Binding affinity of compounds 1-13 and nicotinea
 
N N
X
I II
X
 
 
N structure X Ki (nM) 
1 I CH2NMe2 6000 ± 497 
2 I CH2NHMe > 10.000 
3 I CH2CH2NMe2 > 10.000 
4 I CH2NMe3I 150 ± 6 
5 I CH2CH2NMe3I > 10.000 
6 II NMe 132 ± 8 
7 II NMe2I 45 ± 2 
nicotine   6.8 ± 0. 3 
a Displacement of [3H]-cytisine from rat cortical membranes. See ref. 50 for the experimental 
protocol. Data taken from ref. 44 
 
Among all the output structures found in the hit set, the quinoline derivative VIFLAX51 
(Chart 1) was chosen and its structure simplified in order to give molecules (derived from 7-
aminomethylquinoline) able to interact with the nicotinic receptor. Other quinoline derivatives, 
designed as ligand for the nicotinic receptor, have already been reported in the literature (Chart 
2). Glennon and coworkers52 showed that 5-dimethylaminoquinoline was able to displace [3H]-
nicotine from the nicotinic receptor in rat brain homogenate (Ki 450 nM), while 5-ethylamino-
5,6,7,8-tetrahydroquinoline and its N-methyl derivative are devoid of affinity;53 the same group 
reported that 3-(N-ethyl-N-methylamino)methyl-quinoline and 3-(N-ethyl-N-
methylamino)ethoxyquinoline showed affinity in the micromolar range, while 3-(2-
pyrrolidinyl)quinoline was 9-fold less potent than nicotine.54 Elliott reported that (S)-7-(2-
pyrrolidinyl)methoxyquinoline was able to displace [3H]-cytisine from rat brain homogenate (Ki 
5000 nM).55
The 7-(dimethylaminomethyl)quinoline was synthesized and tested together with its isomers 
in position 5, obtained as by-product from the same synthetic procedure, and 1, its isomers in 
position 6, suggested by molecular modelling studies. Since binding studies showed that only the 
6-substituted quinolines possess some affinity (Chart 2, Table 1), a structure optimization study 
was performed only on compound 1 in order to improve binding affinity:44 while N-dealkylation 
or homologation gave inactive compounds (2 and 3, respectively), the freezing of the alkylamino 
moiety into a pyrrolidine ring was successful since the resulting compound 6 shows nanomolar 
affinity for the nicotinic receptor of rat cerebral cortex. Quaternarization of the nitrogen then 
increased affinity of both 1 and 6, although the effects of this modification are different if we 
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consider the cyclic derivative (the affinity of 7 is 3-fold higher that 6) or the linear compound (4 
is 40-fold more active than 1). It must be remembered that the introduction of a permanent 
positive charge on nicotinic ligands produces in some instances an increase and in others a 
decrease of affinity;56 these differences may reflect a different mode of binding of the quaternary 
ammonium ligands to the nicotinic receptor with respect to their amino derivatives, and/or 
different steric effects within the binding site.50,57  
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Figure 1. Analgesic activity (mice hot-plate test) of compounds 4 (25 µg/mouse, magenta), 6 
(12.5 µg/mouse, blue), 7 (12.5 µg/mouse, red) and 11 (12.5 µg/mouse, green). Epibatidine (50 
ng/mouse, black) was used as reference compound. Each point represents the means of at least 8 
mice. The compounds were injected i.c.v. See ref. 50 for the experimental protocol. *P<0.05 in 
comparison with saline-treated mice (orange). 
 
To check whether these compounds behave as agonists, the analgesic activity of the most 
active substances was measured by means of the hot-plate test on mice (Figure 1).50,58 All the 
tested compounds, when injected intracerebroventricularly (i.c.v.), are able to induce an 
analgesic effect which is completely prevented by mecamylamine at the dose of 5 mg/kg i.p. 
(data not shown). This means that they are able to activate the central nicotinic system, their 
potency being qualitatively in agreement with their rank order of affinity. 
Compounds 1 and 6 (as well as their methiodides 4 and 7) show a distance between the H-
bond acceptor aromatic nitrogen and the cationic nitrogen of 6.5-6.6 Å, therefore higher than that 
proposed by pharmacophoric models,47-49 but in the same range as that obtained considering the 
additional water molecule which connects the nicotine pyridyl nitrogen and the protein in the 
crystal structure of the complex between AChBP and nicotine. The possible presence of a water 
molecule is the basis of the "water-extension concept",59 which suggests that a short ligand such 
as nicotine (N-N distance 4.8 Å) can be transformed into a longer ligand whose distance between 
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the cationic nitrogen and the H-bond forming group (pyridyl nitrogen or water oxigen) is higher 
(6.7 Å in the crystal structure); this would explain the wide range of the proposed 
pharmacophoric distances. In addition, the water molecule could allow the interaction of the 
protein with a ligand having an H-bond acceptor as well as donor group in the suitable position. 
 
N
N N
CH3
CH3
HO I
X
Ki  8nM (ref 50)
X = NHCH3 Ki  58nM (ref 59)
X = N(CH3)2 Ki  510 nM  (ref 59)
X = N(CH3)3+ Ki  470 nM  (ref 59)
Chart 3
 
 
However, ligands are known for which the pharmacophoric distance is higher even than that 
found for nicotine and water: for instance (Chart 3), in 4-(3'-hydroxyphenyl)-1,1-
dimethylpiperazinium iodide (the phenol analogue of DMPP), the distance between the H-bond 
forming group and the cationic nitrogen is 7.5 Å, while for 4-(3-pyridyl)but-3-yn-1-amines the 
low energy conformers have distances higher than 8 Å.59 Both compounds are reported to bind 
with nanomolar affinity to the receptor.50,60 So it can be suggested that ligands dock into the 
active site in a way that allows them to interact with different residues according to their own 
distance between the pharmacophoric points. In this regard, a recently-published study also 
predicts different binding modes of nicotinic ligands within the active site of the receptor.37
 
N N N
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Scheme 1. a) LiAlH4; b) CH3SO2Cl, pyridine; c) Me2NH; d) column chromatography; e) MeI. 
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We thought it interesting to synthesize longer ligands in order to explore the breadth of the 
binding site. Therefore, we designed compounds 8-13: these ligands have pharmacophoric 
distances greater than 8 Å (the cis alkenes 10 and 13), 9 Å (the trans alkenes 9 and 12) or 10 Å 
(the butynes 8 and 11).61 Their synthesis started from 4-(6-quinolinyl)but-3-yn-1-ol44 which was 
transformed into the amine via the methanesulfonate and then quaternarized. LiAlH4 reduction of 
the triple bond gave a mixture of the cis and trans alkenes in a 1:3 ratio, which was transformed 
via the methanesulfonate into the corresponding mixture of amines and then separated by column 
chromatography; the amines were then transformed into the corresponding methiodides (Scheme 
I).62
Binding studies (Table 2) showed that only the methiodides 11 and 12 were able to displace 
[3H]cytisine from rat cerebral cortex, while tertiary amines 8-10 and methiodide 13 were 
completely devoid of affinity. Pharmacological results indicate that long compounds that are able 
to interact with the receptor behave as agonists: in fact, the alkyne 11 shows analgesic properties 
(Figure 1) with an efficacy comparable to that of the other quinolines although its affinity is 10-
fold lower than that of the pirrolidinium compound 7. 
 
Table 2. Binding affinity of compounds 8-13 and nicotinea
 
N
X
 
 
N X Ki (nM) 
8 C≡CCH2CH2NMe2 > 10.000 
9 trans-CH=CHCH2CH2NMe2 > 10.000 
10 cis-CH=CHCH2CH2NMe2 > 10.000 
11 C≡CCH2CH2NMe3I 500 ± 47 
12 trans-CH=CHCH2CH2NMe3I 1350 ± 165 
13 cis-CH=CHCH2CH2NMe3I > 10.000 
nicotine  6.8 ± 0. 3 
a Displacement of [3H]-cytisine from rat cortical membranes; see ref. 50 for the experimental 
protocol. For biological tests, the tertiary amines were transformed into the water-soluble oxalate 
salts. 
 
To see how these compounds could interact with the active site of the α4β2 receptor, the 
model of the rat α4β2 nicotinic receptor (PDB code 1OLE) built by homology modelling on the 
structure of AChBP (PDB code 1I9B)35 was used, applying the Schrödinger induced-fit docking 
protocol.63 In the induced-fit docking both the receptor and the ligand change shape so that they 
more closely conform to each other. The protocol uses the suites Glide for ligand-receptor 
docking and Prime for the protein structure prediction. It works inducing adjustments in the 
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receptor structure and generating multiple poses of the ligand complex, each including unique 
structural modifications of the receptor to fit the ligand pose. The rank of these poses, achieved 
by means of the Glide score function,64 allows finding the best structure of the docked complex. 
From an experimental point of view, default parameters were used, and the binding mode of 
nicotine, epibatidine and other derivatives was compared to that of the quinoline ligands 
synthesized in this study. The geometry of the resulting complexes are reported in Figures 2-4. 
In Figure 2 the binding modes of nicotine, as found in the crystal structure of the complex 
with AChBP (left),31 and docked into the rat α4β2 receptor model (right) are compared. In both 
cases the +NH group of nicotine establishes an H-bond with the carbonyl of Trp147 (Trp143 in 
AChBP), and makes π-cation interactions with the indole ring of the same triptophane and other 
tyrosine residues; in the crystal structure, a H-bond is found between the pyridyl nitrogen and a 
water molecule, which on the other hand interacts with the CO of Leu112 and the NH of 
Met114. In the docking complex the orientation of the heteroaromatic ring is similar, but, since 
water molecules were not included in the docking experiments, no H-bond is established. 65
 
 
Trp147/α
Tyr195/α
Phe117/β
Leu119/β
Tyr192
Trp143
Met114
Leu112
 
 
Figure 2. Binding mode of (S)-nicotine in the active site of AChBP (left) and in the binding site 
of rat α4β2 receptor model (right). Nicotine is shown as stick models, with their C atom yellow. 
The residues interacting with the ligands, as well as Phe117 and Leu119, are shown as stick 
models. Hydrogen bond interactions are shown in green. 
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Tyr195/α
Tyr91/α
Phe117/β
Leu119/β
Trp147/α
Thr148/α
Trp147/α
Tyr195/α
Tyr188/α
Asp150/α
Phe117/β
Leu119/β
 
 
Figure 3. Docking of (1R,2R,4S)-epibatidine (left) and 3-OH-DMPP (right) in the binding site of 
rat α4β2 receptor model. Ligands are shown as stick models, with their C atom yellow. The 
residues interacting with the ligands, as well as Phe117 and Leu119 in the β subunit, are shown 
as stick models. Hydrogen bond interactions are shown in green. 
 
The binding of (1R,2R,4S)-epibatidine (Figure 3, left) with the rat α4β2 receptor model is 
predicted to occur through two hydrogen bonds of the +NH2 group with the carbonyl of Trp147 
and the phenolic OH of Tyr91, while the pyridyl nitrogen accepts a H-bond from Thr148 
hydroxyl group. This orientation is somehow different from that found by other researchers 
which applied a standard (no induced fit) docking procedure on the same model 1OLE.37 3-
Hydroxy-DMPP (Figure 3, right), being a quaternary ammonium derivative, can only establish 
π-cation interactions with the aromatic residues of the binding site, while making a H-bond 
through the phenol OH with Asp150, a residue shown by site-directed mutagenesis studies on the 
muscle-type receptor to be involved in the binding of agonists and competitive antagonists.66
In Figure 4 the docking of the quinoline derivatives 6 and 7 is reported. The (S) isomer of the 
tertiary amine 667 docks in a way similar to that of nicotine, therefore establishing H-bond and π-
cation interaction with Trp147, but, as for nicotine, the heteroaromatic nitrogen is not involved in 
a direct H-bond with the receptor, even though it is directed towards Leu119/β, the analogue of 
the AChBP residue Met114. On the contrary, the ammonium derivative 7 can establish a H-bond 
with the ε-amino group of Lys77 in addition to π-cation interactions with Trp147 and other 
aromatic residues; this is made possible by the lack of H-bond involving the cationic nitrogen, 
thus allowing a slightly different arrangement of this ammonium derivative within the binding 
site. 
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Trp147/α
Phe117/β
Leu119/β
Trp147/α
Tyr195/α Lys77/β
Phe117/β
Leu119/β
 
 
Figure 4. Docking of (S)-6 (left) and (S)-7 (right) in the binding site of rat α4β2 receptor model. 
Ligands are shown as stick models, with their C atom yellow. The residues interacting with the 
ligands, as well as Phe117 and Leu119 in the β subunit, are shown as stick models. Hydrogen 
bond interactions are shown in green. The (S)-isomer of 6 is docked with the protonated nitrogen 
atom in the R configuration. 
 
The docking of the alkyne 11 into the active site of the receptor (Figure 5) results in a 
binding mode similar to 7: the anchoring π-cation interaction with Trp147 in the α subunit allows 
the quinoline ring to be inserted more deeply into the β subunit, making a strong H-bond with 
Lys161. Since the kind of β subunit is thought to be the major factor in determining agonist 
affinity,68 the synthesis of agonists able to interact more deeply into the β subunits may be useful 
to find new selective ligands, as recently demonstrated by Kozikowski and coworkers.69
 
 
Conclusions 
 
In conclusion, we have synthesized new nicotinic agonists that can be useful as tools to study the 
breadth of the binding site of the receptor; these compounds will be characterized further by 
checking selectivity for the nicotinic receptor subtypes and enantioselectivity (as far as the 
pyrrolidine derivatives are concerned); hopefully they can give useful suggestions also for 
designing selective ligands for the characterization of nicotinic receptor subtype. 
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Trp147/α Lys161/β
Phe117/β
Leu119/β
 
 
Figure 5. Docking of (S)-11 in the binding site of rat α4β2 receptor model; 11 is shown as stick 
models, with their C atom yellow. The residues interacting with the ligands, as well as Phe117 
and Leu119 in the β subunits, are shown as stick models. Hydrogen bond interactions are shown 
in green. 
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